Literature DB >> 15607966

Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

Sandrine Valsesia-Wittmann1, Maud Magdeleine, Sébastien Dupasquier, Elisabeth Garin, Anne-Catherine Jallas, Valérie Combaret, Alexander Krause, Philippe Leissner, Alain Puisieux.   

Abstract

N-Myc oncogene amplification is a frequent event in neuroblastoma and is strongly correlated with advanced disease stage and treatment failure. Similarly to c-Myc oncogenic activation, N-Myc deregulation promotes both cell proliferation and p53-dependent apoptosis by sensitizing cells to a variety of insults. Intriguingly, p53 mutations are uncommon in neuroblastomas, strongly suggesting that an alternative cooperating event circumvents this safeguard against oncogene-driven neoplasia. By performing a pangenomic cDNA microarray analysis, we demonstrate that human Twist is constantly overexpressed in N-Myc-amplified neuroblastomas. H-Twist overexpression is responsible for the inhibition of the ARF/p53 pathway involved in the Myc-dependent apoptotic response. This oncogenic cooperation of two key regulators of embryogenesis causes cell transformation and malignant outgrowth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15607966     DOI: 10.1016/j.ccr.2004.09.033

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  98 in total

1.  Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells.

Authors:  Yoshihiro Takeyama; Mitsuo Sato; Mihoko Horio; Tetsunari Hase; Kenya Yoshida; Toshihiko Yokoyama; Harunori Nakashima; Naozumi Hashimoto; Yoshitaka Sekido; Adi F Gazdar; John D Minna; Masashi Kondo; Yoshinori Hasegawa
Journal:  Cancer Lett       Date:  2010-05-07       Impact factor: 8.679

2.  Silencing of CDC42 inhibits neuroblastoma cell proliferation and transformation.

Authors:  Sora Lee; Brian T Craig; Carmelle V Romain; Jingbo Qiao; Dai H Chung
Journal:  Cancer Lett       Date:  2014-09-28       Impact factor: 8.679

3.  Demonstration of Tightly Radiation-Controlled Molecular Switch Based on CArG Repeats by In Vivo Molecular Imaging.

Authors:  Ya-Ju Hsieh; Luen Hwu; Chien-Chih Ke; Ai-Lin Huang; Fu-Du Chen; Shyh-Jong Wu; Sharon Chia-Ju Chen; Yong-Hua Zhao; Ren-Shyan Liu
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 4.  Inflammation fuels tumor progress and metastasis.

Authors:  Jingyi Liu; Pengnian Charles Lin; Binhua P Zhou
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

5.  HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.

Authors:  Jie Chen; Jun Xia; Yong-lin Yu; Si-qun Wang; Yi-bing Wei; Fei-yan Chen; Gang-yong Huang; Jing-sheng Shi
Journal:  Tumour Biol       Date:  2013-10-05

6.  Prognostic value of Twist and E-cadherin in patients with osteosarcoma.

Authors:  Ke Yin; Qiande Liao; Hongbo He; Da Zhong
Journal:  Med Oncol       Date:  2012-07-31       Impact factor: 3.064

7.  TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214.

Authors:  G Yin; R Chen; A B Alvero; H-H Fu; J Holmberg; C Glackin; T Rutherford; G Mor
Journal:  Oncogene       Date:  2010-04-19       Impact factor: 9.867

8.  Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths.

Authors:  Marjon A Smit; Daniel S Peeper
Journal:  Aging (Albany NY)       Date:  2010-10       Impact factor: 5.682

9.  A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response.

Authors:  Sanjay Chandriani; Eirik Frengen; Victoria H Cowling; Sarah A Pendergrass; Charles M Perou; Michael L Whitfield; Michael D Cole
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

10.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.